Better drugs through AI? Insitro CEO on what machine learning can teach Big Pharma
Artificial intelligence is changing the way industries do business. But executives in the pharmaceutical industry are still ...
Why Is Eli Lilly and Company (LLY) Among Ken Fisher’s Top Stock Picks Heading Into 2025?
We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are ...
Mastercard, Broadcom, Pfizer Among Two Dozen Companies To Announce Dividend Increases In December
It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...
Potential conflicts of interest may haunt Dr. Oz’s confirmation to run Medicare, Medicaid
Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.
Jaguar's rebrand has been criticized as 'woke.' Marketing experts say it's either 'bonkers' — or a genius disruption.
Jaguar's rebranding marks a radical identity shift for the carmaker. One ad expert called it "bonkers." Others said it was a ...
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
Eli Lilly and Novo Nordisk’s obesity moat just got stronger
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
FiercePharma6h
Race is on for oral obesity drugs with multiple phase 3 trials vying for next-gen status in a $126B market
Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...
Why Is Eli Lilly and Company (LLY) Among Louis Navellier’s Top Stock Picks Heading Into 2025?
We recently compiled a list of the Louis Navellier’s Top 10 Stock Picks Heading into 2025. In this article, we are going to ...
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?
The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...